BioAtla (NASDAQ:BCAB) Lowered to Neutral Rating by HC Wainwright

HC Wainwright cut shares of BioAtla (NASDAQ:BCAB) from a buy rating to a neutral rating in a research note published on Wednesday morning, MarketBeat.com reports. HC Wainwright also issued estimates for BioAtla’s Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.46) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of BioAtla in a report on Monday, September 16th.

BioAtla Stock Down 8.8 %

BCAB stock opened at $1.56 on Wednesday. The business has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.87. The stock has a market cap of $75.40 million, a price-to-earnings ratio of -0.92 and a beta of 1.03. BioAtla has a fifty-two week low of $1.14 and a fifty-two week high of $4.02.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million for the quarter. During the same period in the previous year, the company earned ($0.70) EPS. As a group, sell-side analysts anticipate that BioAtla will post -1.52 EPS for the current year.

Institutional Trading of BioAtla

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in shares of BioAtla in the second quarter valued at about $872,000. Scion Asset Management LLC purchased a new position in shares of BioAtla in the 2nd quarter valued at approximately $869,000. Price T Rowe Associates Inc. MD acquired a new position in shares of BioAtla in the first quarter valued at approximately $45,000. Acadian Asset Management LLC raised its stake in shares of BioAtla by 57.6% during the first quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock worth $532,000 after purchasing an additional 56,748 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of BioAtla during the first quarter worth $103,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.